PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application
Portfolio Pulse from
PharmaTher Holdings Ltd. has been granted a post-complete response letter clarification meeting with the FDA regarding their ketamine Abbreviated New Drug Application. This follows a complete response letter issued by the FDA in October 2024.
November 13, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
PharmaTher Holdings Ltd. has been granted a meeting with the FDA to clarify issues raised in a complete response letter for their ketamine drug application. This is a critical step in addressing regulatory concerns and potentially advancing the application process.
The meeting with the FDA is a necessary step for PharmaTher to address the issues raised in the complete response letter. While it does not guarantee approval, it is a positive move towards resolving regulatory concerns. The impact on the stock price is neutral in the short term as the outcome of the meeting is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100